Oops! This page seems to have moved.
Our website recently re-launched, and a lot of content has been shuffled around.
We've done a search for you below to see if we can help find what you're looking for.
Searching for: 'arthritis information information sheets'
About your Privacy, Disclaimer and Complaints Management
Privacy policy & disclaimer of Australia Australia. This website is owned and operated by Arthritis Foundation of Australia T/as Arthritis Australia. Last updated and reviewed: 19th July 2017
Tocilizumab
Tocilizumab (brand name Actemra) belongs to a new class of medicines called biological disease modifying antirheumatic drugs (biological DMARDs or bDMARDs). These medicines block natural substances called cytokines, which are found in excessive amounts in the blood and joints of people with rheumatoid arthritis. The increased levels of cytokines cause inflammation, which results in symptoms of pain, joint swelling and stiffness, and can lead to joint damage.
Resource links
Find links to other organisations and resources that may be helpful.
Self-injecting low dose methotrexate for the treatment of arthritis
This information is useful if your doctor has recommended injections of methotrexate either for better efficacy or to reduce side-effects. It gives information about how you, or a friend or family member, can safely inject methotrexate, the steps to follow and the equipment you will need. For general information on methotrexate, refer to the “Methotrexate” patient information.
Arthritis Australia launches new Multicultural Resources
Non-English-speaking communities will have improved access to information about arthritis and its management with the launch today of a new series of arthritis information sheets in fourteen different languages.
Etanercept
Etanercept belongs to a class of medicines called biological disease modifying antirheumatic drugs (biological DMARDs or bDMARDs). hese medicines block substances, produced by arthritic tissues, called cytokines. These cytokines are found in excessive amounts in the blood and joints of people with rheumatoid arthritis, psoriatic arthritis, juvenile arthritis and ankylosing spondylitis.
Guselkumab
Guselkumab belongs to a class of medicines called biological disease-modifying antirheumatic drugs (biological DMARDs or bDMARDs). People with psoriatic arthritis and psoriasis have increased levels of a protein called interleukin-23 (IL-23) which can cause pain and swelling in the joints. Guselkumab works by blocking the activity of IL-23 and hence reduces the inflammation. Guselkumab is...
Adalimumab
Adalimumab (brand name Humira) belongs to a new class of medicines called biological disease modifying antirheumatic drugs (biological DMARDs or bDMARDs). These medicines block natural substances, called cytokines, which are found in excessive amounts in the blood and joints of people with rheumatoid arthritis, psoriatic arthritis, juvenile arthritis and ankylosing spondylitis.
Mycophenolate
Mycophenolate mofetil (brand name CellCept, Imulate, Ceptolate) and mycophenolate sodium (brand name Myfortic) are both converted in the body to mycophenolic acid, which is used to treat immune related diseases such as systemic lupus erythematosus (also known as lupus or SLE), autoimmune vasculitis (inflammation of blood vessels), inflammatory bowel disease such as Crohn’s disease, and other kidney or skin disorders.
Infliximab
Infliximab (brand name: Remicade(r)) belongs to a group of medicines called biological disease modifying antirheumatic drugs (biological DMARDs or bDMARDs). These medicines block natural substances, produced by arthritic tissues, called cytokines, which are are found in excessive amounts in the blood and joints of people with rheumatoid arthritis, psoriatic arthritis, juvenile arthritis and ankylosing spondylitis.
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox:
